Recognition of Non-Operating Income (Subsidy Income)
STELLA PHARMA CORPORATION
Research grant for angiosarcoma, research grant for meningioma, and subsidy related to the Drug Discovery Support Promotion Project and the Practical Application Support Project Before Designation of Orphan Drugs for Rare Diseases
¥29.601 million (non-operating income and subsidy income)
Cumulative first-quarter period of the fiscal year ending March 2027 (from 1 April 2026 to 30 June 2026)
There is no change to the earnings forecast for the fiscal year ending March 2027.
The recognized subsidy income will be reflected in the first-quarter earnings report, and the earnings forecast for the fiscal year ending March 2027 will remain unchanged.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income (Subsidy Income) |
| Date of occurrence | The cumulative first-quarter period of the fiscal year ending March 2027, from 1 April 2026 to 30 June 2026 (single date during the period: Not disclosed) |
| Subject Entity | STELLA PHARMA CORPORATION |
| Target Locations / Products | Research grant for angiosarcoma, research grant for meningioma, and subsidy related to the Drug Discovery Support Promotion Project and the Practical Application Support Project Before Designation of Orphan Drugs for Rare Diseases |
| Amount of Impact on Business Performance | ¥29.601 million (non-operating income and subsidy income) |
| Accounting period in which recognized | Cumulative first-quarter period of the fiscal year ending March 2027 (from 1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | There is no change to the earnings forecast for the fiscal year ending March 2027. |
| Outlook | The recognized subsidy income will be reflected in the first-quarter earnings report, and the earnings forecast for the fiscal year ending March 2027 will remain unchanged. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because research grants from the National Institutes of Biomedical Innovation, Health and Nutrition for testing and research, and subsidies from the Japan Agency for Medical Research and Development (AMED), were recognized.